Marker Therapeutics Inc MRKR Q1 2026 Earnings EPS Beat Expectations Amid Development Stage Operations AGYS Q1 2026 Earnings Strong EPS Beat Despite Modest Stock Decline AUTL Q1 2026 Earnings Slight EPS Miss No Revenue Stock Gains 3 Scholar Rock Q1 2026 Earnings WiderthanExpected Loss as PreRevenue Biotech Advances Pipeline LOCO Q1 2026 Earnings Strong EPS Beat Highlights Operational Resilience in Challenging Environment SYRE Q1 2026 Earnings EPS Miss Amidst No Revenue Focus on Pipeline Progress